WO2002027325A1 - Verfahren zur diagnose der laktose-intoleranz und diagnosekit zur durchführung des verfahrens - Google Patents
Verfahren zur diagnose der laktose-intoleranz und diagnosekit zur durchführung des verfahrens Download PDFInfo
- Publication number
- WO2002027325A1 WO2002027325A1 PCT/EP2001/010767 EP0110767W WO0227325A1 WO 2002027325 A1 WO2002027325 A1 WO 2002027325A1 EP 0110767 W EP0110767 W EP 0110767W WO 0227325 A1 WO0227325 A1 WO 0227325A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactose
- sample
- labeled
- application
- serum
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
Definitions
- the present invention relates to a method for diagnosing lactose intolerance in patients by oral administration of defined amounts of lactose and subsequent determination of metabolites of lactose, and a diagnostic kit for carrying out the method.
- Lactose intolerance is a very common phenomenon worldwide and leads to a more or less severe indigestion caused by milk and milk products.
- Lacose intolerance is generally due to the lack of the enzyme lactase, the formation of which is caused by a gene on chromosome 2. This gene determines the point in time when humans stop producing lactase. Depending on the ethnicity, this may be the case sooner or later. In earlier times in the history of development, humans, like many other mammals, always lost the enzyme when they were no longer fed on breast milk (cf. Pharm. Ztg. No. 9 • 145th year • March 2, 2000). For the diagnosis of lactose intolerance, the H 2 breath test is most often used today simply and meaningfully.
- the patient drinks a solution of 50 g lactose in water.
- the exhaled hydrogen is then repeatedly measured by gas chromatography over 4 hours. In this way you get not only a qualitative, but also a quantitative statement about the lactase deficiency.
- Lactose intolerance is now regarded as a disease that can only be treated symptomatically. However, there is now the possibility of taking the enzyme lactase in the form of capsules, tablets or solution and thereby compensating for the deficit in lactase.
- the determination of the blood glucose has the further disadvantage that the blood glucose level can be changed by secondary influences, for example increased adrenaline release due to stress.
- the object of the invention is to provide a better, cheaper and more precise method for diagnosing lactose intolerance which does not have the disadvantages mentioned above.
- This object is achieved according to the invention by oral application of defined amounts of lactose and subsequent determination of metabolites of lactose, the applied lactose containing 99% 13 C-labeled lactose, preferably in amounts of 5 to 30 mg.
- the content of 13 C-labeled glucose is determined in a blood sample taken at a defined time after the application.
- the 13 C-lactose is preferably applied in the form of a gelatin capsule. This makes it possible for the 13 C-lactose to get into the small intestine without being absorbed in the stomach.
- the method can also be improved in terms of informative value by additionally determining the content of 13 C-labeled lactose and / or 13 C-labeled lactic acid in a stool sample obtained some time after the time of the blood withdrawal. This additional determination is only necessary if the examination of the serum sample for glucose shows no significant increase in i3 C and thus the lactose intolerance is actually already established.
- the method according to the invention manages with a significantly smaller amount of lactose, namely 5 to 30 g of 99% 13 C-lactose in one capsule. This lower amount does not cause any discomfort during the diagnostic procedure in patients with severe lactose intolerance.
- the 13 C content in the serum samples and / or the stool samples is determined according to the invention in particular with the aid of modern mass spectrography with upstream gas chromatography or elementary analysis.
- the central laboratory should primarily analyze only the serum samples. If stool samples are also sent in, they should only be examined if the corresponding serum sample has not shown a significant increase in 13 C-labeled glucose. If there is a normal increase in the 13 C content compared to standard samples with a known 13 C content, it is already indicated that lactose is well tolerated and that it is sufficiently broken down to glucose by lactase. Only if there is no or a significantly smaller increase in the 1 C content can an examination of the stool sample determine whether the lactose intolerance is very strong or weak.
- the test shows a normal increase in the 13 C content and milk and milk products are still poorly tolerated, the disease is other than the widespread lactose intolerance.
- the method according to the invention can thus also be used for differential diagnosis. This group of patients cannot be helped by taking lactase supplements.
- 0.3 to 0.5 ml of capillary blood is removed from the finger or earlobe from the fasted subject.
- the subject then takes a gelatin capsule with 5 to 30 mg of 13 C-labeled lactose. 30 to 60 minutes after taking the labeled lactose, 0.3 to 0.5 ml of blood are again taken as described above.
- the blood samples are turned into serum by centrifugation won. Filters with a higher molecular weight (eg lipids and proteins) are removed from the serum samples.
- the filtrates are burned using an elementary analysis.
- the CO 2 formed, among other things, from glucose is passed into an isotope mass spectrometer, which is used to determine the 13 C content. As described above, both blood samples are evaluated. If a difference ⁇ of less than 1% o is detected between the blood samples before and after taking 13 C-lactose, there is a lactose intolerance.
- the patient takes a sample from the next chair and carries it with the spatula into a sample container.
- the next stool is generally 2 to 4 hours after taking the capsule.
- An aqueous extract is made from the stool samples in the laboratory and this is examined for 13 C-lactose and / or 13 C-lactic acid. The presence of 13 C-lactose or 13 C-lactic acid confirms the lactose intolerance.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Electrotherapy Devices (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001291870A AU2001291870A1 (en) | 2000-09-27 | 2001-09-18 | Method for diagnosing lactose intolerance and diagnosis kit for carrying out themethod |
US10/380,466 US7037487B2 (en) | 2000-09-27 | 2001-09-18 | Method for diagnosing lactose intolerance and diagnostic kit for performing the method |
DE50108257T DE50108257D1 (de) | 2000-09-27 | 2001-09-18 | Verfahren zur diagnose der laktose-intoleranz und diagnosekit zur durchführung des verfahrens |
AT01972068T ATE311600T1 (de) | 2000-09-27 | 2001-09-18 | Verfahren zur diagnose der laktose-intoleranz und diagnosekit zur durchführung des verfahrens |
EP01972068A EP1320757B1 (de) | 2000-09-27 | 2001-09-18 | Verfahren zur diagnose der laktose-intoleranz und diagnosekit zur durchführung des verfahrens |
US11/355,979 US20060140861A1 (en) | 2000-09-27 | 2006-02-17 | Method for diagnosing lactose intolerance and diagnostic kit for performing the method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10060989.9 | 2000-09-27 | ||
DE10060989A DE10060989B4 (de) | 2000-09-27 | 2000-09-27 | Verfahren zur Diagnose der Laktose-Intoleranz und Diagnosekit zur Durchführung des Verfahrens |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/355,979 Continuation US20060140861A1 (en) | 2000-09-27 | 2006-02-17 | Method for diagnosing lactose intolerance and diagnostic kit for performing the method |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002027325A1 true WO2002027325A1 (de) | 2002-04-04 |
Family
ID=7666234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/010767 WO2002027325A1 (de) | 2000-09-27 | 2001-09-18 | Verfahren zur diagnose der laktose-intoleranz und diagnosekit zur durchführung des verfahrens |
Country Status (8)
Country | Link |
---|---|
US (2) | US7037487B2 (de) |
EP (1) | EP1320757B1 (de) |
AT (1) | ATE311600T1 (de) |
AU (1) | AU2001291870A1 (de) |
DE (2) | DE10060989B4 (de) |
DK (1) | DK1320757T3 (de) |
ES (1) | ES2250478T3 (de) |
WO (1) | WO2002027325A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10060989B4 (de) * | 2000-09-27 | 2004-02-19 | Aygen, Sitke, Dr. | Verfahren zur Diagnose der Laktose-Intoleranz und Diagnosekit zur Durchführung des Verfahrens |
DK1553987T3 (da) * | 2002-10-26 | 2007-12-27 | Infai Inst Fuer Biomedizinisch | Fremgangsmåde til bestemmelse af tömningen af maven med et testmåltid mærket med 13C |
WO2008057265A2 (en) * | 2006-10-27 | 2008-05-15 | University Of Maryland | Single nucleotide polymorphisms and the identification of lactose intolerance |
JP2012518657A (ja) | 2009-02-25 | 2012-08-16 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 併用抗癌治療 |
DE102011005600A1 (de) * | 2011-03-16 | 2012-09-20 | Siemens Aktiengesellschaft | Detektion von Organismen und Bestimmung der Resistenz mit Hilfe der Massenspektrometrie |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
CN107941799A (zh) * | 2017-12-20 | 2018-04-20 | 珠海科域生物工程股份有限公司 | 一种粪便样本检测试纸及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5640014A (en) * | 1995-05-15 | 1997-06-17 | San Jose State University Foundation | Laser diode spectrometer for analyzing the ratio of isotopic species in a substance |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10060989B4 (de) * | 2000-09-27 | 2004-02-19 | Aygen, Sitke, Dr. | Verfahren zur Diagnose der Laktose-Intoleranz und Diagnosekit zur Durchführung des Verfahrens |
-
2000
- 2000-09-27 DE DE10060989A patent/DE10060989B4/de not_active Expired - Fee Related
-
2001
- 2001-09-18 US US10/380,466 patent/US7037487B2/en not_active Expired - Fee Related
- 2001-09-18 EP EP01972068A patent/EP1320757B1/de not_active Expired - Lifetime
- 2001-09-18 ES ES01972068T patent/ES2250478T3/es not_active Expired - Lifetime
- 2001-09-18 AU AU2001291870A patent/AU2001291870A1/en not_active Abandoned
- 2001-09-18 AT AT01972068T patent/ATE311600T1/de not_active IP Right Cessation
- 2001-09-18 WO PCT/EP2001/010767 patent/WO2002027325A1/de active IP Right Grant
- 2001-09-18 DE DE50108257T patent/DE50108257D1/de not_active Expired - Lifetime
- 2001-09-18 DK DK01972068T patent/DK1320757T3/da active
-
2006
- 2006-02-17 US US11/355,979 patent/US20060140861A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5640014A (en) * | 1995-05-15 | 1997-06-17 | San Jose State University Foundation | Laser diode spectrometer for analyzing the ratio of isotopic species in a substance |
Non-Patent Citations (6)
Title |
---|
HERMANS MARC M H ET AL: "The relationship between lactose tolerance test results and symptoms of lactose intolerance.", AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 92, no. 6, 1997, pages 981 - 984, XP001027136, ISSN: 0002-9270 * |
HIELE M ET AL: "CARBON-13 DIOXIDE BREATH TEST USING NATURALLY CARBON-13-ENRICHED LACTOSE FOR DETECTION OF LACTASE DEFICIENCY IN PATIENTS WITH GASTROINTESTINAL SYMPTOMS", JOURNAL OF LABORATORY AND CLINICAL MEDICINE, vol. 112, no. 2, 1988, pages 193 - 200, XP001027178, ISSN: 0022-2143 * |
MURRAY R D ET AL: "COMPARATIVE ABSORPTION OF CARBON-13 GLUCOSE AND CARBON-13 LACTOSE BY PREMATURE INFANTS", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 51, no. 1, 1990, pages 59 - 66, XP001027415, ISSN: 0002-9165 * |
PEUHKURI K ET AL: "Wide variations in the testing of lactose tolerance: Results of a questionnaire study in Finnish health care centres.", SCANDINAVIAN JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION, vol. 60, no. 4, July 2000 (2000-07-01), pages 291 - 298, XP001027414, ISSN: 0036-5513 * |
VONK R J ET AL: "THE 13C/2H-GLUCOSE TEST FOR DETERMINATION OF SMALL INTESTINAL LACTASE ACTIVITY", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, BLACKWELL SCIENTIFIC PUBLICATIONS, XX, vol. 31, no. 3, 2001, pages 226 - 233, XP000998471, ISSN: 0014-2972 * |
VONK ROEL J ET AL: "Small intestinal and colonic factors involved in lactose intolerance.", FASEB JOURNAL, vol. 15, no. 4, 7 March 2001 (2001-03-07), Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001;Orlando, Florida, USA; March 31-April 04, 2001, pages A277, XP001027262, ISSN: 0892-6638 * |
Also Published As
Publication number | Publication date |
---|---|
AU2001291870A1 (en) | 2002-04-08 |
US20060140861A1 (en) | 2006-06-29 |
DE50108257D1 (de) | 2006-01-05 |
US7037487B2 (en) | 2006-05-02 |
DE10060989A1 (de) | 2002-04-18 |
DE10060989B4 (de) | 2004-02-19 |
ES2250478T3 (es) | 2006-04-16 |
EP1320757B1 (de) | 2005-11-30 |
US20040087837A1 (en) | 2004-05-06 |
ATE311600T1 (de) | 2005-12-15 |
DK1320757T3 (da) | 2006-03-06 |
EP1320757A1 (de) | 2003-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60120487T2 (de) | Verfahren zur detektion von vitamin d metaboliten | |
DE69333334T2 (de) | Verfahren zur vorhersage von frühgeburten | |
EP1904082B1 (de) | VERFAHREN ZUR BESTIMMUNG DER KONZENTRATION DER ADIPOZYTAREN FORM DES FATTY ACID BINDUNG PROTEIN (A-FABP, FABP4, aP2) | |
WO2007014667A9 (de) | In vitro verfahren zur diagnose von neurodegenerativen erkrankungen | |
EP1320757B1 (de) | Verfahren zur diagnose der laktose-intoleranz und diagnosekit zur durchführung des verfahrens | |
WO2019158718A1 (de) | Methode zur bestimmung der totalen histamin-abbaukapazität in biologischen proben | |
DE2531176A1 (de) | Verfahren zum nachweis von gonorrhoeantikoerpern | |
DE102006023175A1 (de) | In vitro Verfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen | |
DE60038614T2 (de) | Verfahren zur diagnose von synovialen oder osteoartikulären erkrankungen | |
DE69024348T2 (de) | Verfahren zum nachweis des diabetischen zustandes | |
DE3780446T2 (de) | Verfahren zur feststellung von schwangerschaftsstoerungen. | |
WO2005050219A1 (de) | Schnelltest zur diagnose der alzheimerschen erkrankung | |
DE69213114T2 (de) | Immunoassay von menschlicher Granulocyte-Elastase | |
DE102019218597B4 (de) | Verfahren zum Erstellen eines Befundes zur Funktionalität eines anorexigenen Signalwegs für einen Patienten | |
EP1415159B1 (de) | Verfahren und diagnosekit zur diagnose von helicobacter pylori | |
EP1560603B1 (de) | Verfahren zur messung des metabolismus der bauchspeicheldrüse | |
DE69403093T2 (de) | Test zur Bestimmung des Glaukoms (POAG) durch Testen peripherer Blutzellen auf 3-Alpha-Hydroxysteroiddehydrogenase Aktivität und dazu geeignetes Kit | |
EP0435890B1 (de) | Verfahren zum nachweis der funktionsfähigkeit der nierentubuli | |
DE60313972T2 (de) | Blutuntersuchungsmethode zur Früherkennung von Krankeiten wie z.B: Diabetes | |
DE1906743A1 (de) | Mittel fuer die Diagnose von Vitamin-B12-Mangel und gegebenenfalls Folsaeuremangel und Verfahren zu dessen Anwendung | |
DE2537488C2 (de) | Mittel zur Durchführung eines Harnsäure-Belastungstests | |
DE69028056T2 (de) | Behandlung von nichtulzerativer Dyspepsie mit Cyproheptadin | |
DE2535279C3 (de) | Verfahren zum Analysieren des Thyroid-Hormongehaltes einer Blutserumprobe | |
Claus et al. | Ise eine Zunahme des Hirnvolumens abstinenter Alkoholiker Rehydratationsfolge? | |
DE102008061174A1 (de) | Verfahren zur Identifikation von biologischen Proben sowie Kit mit einem Identifikationssystem für biologische Proben |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001972068 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10380466 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2001972068 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001972068 Country of ref document: EP |